147 related articles for article (PubMed ID: 19026523)
1. Antifungal activity of anidulafungin, a product of Aspergillus nidulans, against Aspergillus nidulans.
Hof H; Dietz A
Int J Antimicrob Agents; 2009 Mar; 33(3):285-6. PubMed ID: 19026523
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp.
Martos AI; Martín-Mazuelos E; Romero A; Serrano C; González T; Almeida C; Puche B; Cantón E; Pemán J; Espinel-Ingroff A
Diagn Microbiol Infect Dis; 2012 May; 73(1):53-6. PubMed ID: 22480568
[TBL] [Abstract][Full Text] [Related]
3. The echinocandin B producer fungus Aspergillus nidulans var. roseus ATCC 58397 does not possess innate resistance against its lipopeptide antimycotic.
Tóth V; Nagy CT; Pócsi I; Emri T
Appl Microbiol Biotechnol; 2012 Jul; 95(1):113-22. PubMed ID: 22555909
[TBL] [Abstract][Full Text] [Related]
4. Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.
Cafini F; Sevillano D; Alou L; Gómez-Aguado F; Corcuera MT; González N; Guinea J; Prieto J
Rev Esp Quimioter; 2012 Mar; 25(1):47-55. PubMed ID: 22488542
[TBL] [Abstract][Full Text] [Related]
5. Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
Saribas Z; Yurdakul P; Cetin-Hazirolan G; Arikan-Akdagli S
Mycoses; 2012 Mar; 55(2):156-60. PubMed ID: 21668525
[TBL] [Abstract][Full Text] [Related]
6.
Raffetin A; Courbin V; Jullien V; Dannaoui E
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038263
[No Abstract] [Full Text] [Related]
7. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
10. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
11. Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy.
Plummer R; Bodkin J; Power D; Pantarat N; Bubb WA; Kuchel PW; Sorrell TC
Antimicrob Agents Chemother; 2007 Nov; 51(11):4077-84. PubMed ID: 17785514
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.
Bowman JC; Abruzzo GK; Flattery AM; Gill CJ; Hickey EJ; Hsu MJ; Kahn JN; Liberator PA; Misura AS; Pelak BA; Wang TC; Douglas CM
Antimicrob Agents Chemother; 2006 Dec; 50(12):4202-5. PubMed ID: 17015628
[TBL] [Abstract][Full Text] [Related]
13. Initial results from a longitudinal international surveillance programme for anidulafungin (2003).
Messer SA; Kirby JT; Sader HS; Fritsche TR; Jones RN
J Antimicrob Chemother; 2004 Dec; 54(6):1051-6. PubMed ID: 15564286
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition.
Morikawa H; Tomishima M; Kayakiri N; Araki T; Barrett D; Akamatsu S; Matsumoto S; Uchida S; Nakai T; Takeda S; Maki K
Bioorg Med Chem Lett; 2014 Feb; 24(4):1172-5. PubMed ID: 24468413
[TBL] [Abstract][Full Text] [Related]
15. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
[TBL] [Abstract][Full Text] [Related]
17. Aspergillus nidulans galactofuranose biosynthesis affects antifungal drug sensitivity.
Alam MK; El-Ganiny AM; Afroz S; Sanders DA; Liu J; Kaminskyj SG
Fungal Genet Biol; 2012 Dec; 49(12):1033-43. PubMed ID: 23078837
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo.
Calvo E; Pastor FJ; Mayayo E; Guarro J
Int J Antimicrob Agents; 2011 Oct; 38(4):360-3. PubMed ID: 21824751
[TBL] [Abstract][Full Text] [Related]
19. Mitogen-activated protein kinases MpkA and MpkB independently affect micafungin sensitivity in Aspergillus nidulans.
Yoshimi A; Fujioka T; Mizutani O; Marui J; Hagiwara D; Abe K
Biosci Biotechnol Biochem; 2015; 79(5):836-44. PubMed ID: 25727969
[TBL] [Abstract][Full Text] [Related]
20. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
